Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow
18 avr. 2022 16h30 HE
|
Profound Medical Corp.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results
03 mars 2022 16h03 HE
|
Profound Medical Corp.
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in March Investor Conferences
02 mars 2022 08h00 HE
|
Profound Medical Corp.
TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
01 mars 2022 07h00 HE
|
Profound Medical Corp.
TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow
10 févr. 2022 16h30 HE
|
Profound Medical Corp.
TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
08 févr. 2022 16h30 HE
|
Profound Medical Corp.
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
18 janv. 2022 07h33 HE
|
Profound Medical Corp.
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Kenneth Knudson Joins Profound Medical as Chief Commercial Officer
05 janv. 2022 08h00 HE
|
Profound Medical Corp.
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Third Quarter 2021 Financial Results
04 nov. 2021 16h03 HE
|
Profound Medical Corp.
TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in November Virtual Investor Conferences
01 nov. 2021 16h30 HE
|
Profound Medical Corp.
TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...